Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. - Wikidata - wikimedia - TriplyDB

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

http://www.wikidata.org/entity/Q33403458

about

The role of PARP in DNA repair and its therapeutic exploitation PARP inhibition: PARP1 and beyond Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.BRCA1 Mutation: A Predictive Marker for Radiation Therapy?An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.Predicting enhanced cell killing through PARP inhibition.Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo Therapeutic applications of PARP inhibitors: anticancer therapy and beyond Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation.Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?A review of PARP inhibitors: from bench to bedside.The clinical development of inhibitors of poly(ADP-ribose) polymerase.Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.Predictive biomarkers for cancer therapy with PARP inhibitors.Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.The potential of PARP inhibitors in neuro-oncology.NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.Temozolomide may induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells.Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.The development of PARP as a successful target for cancer therapy.The Shc protein RAI promotes an adaptive cell survival program in hypoxic neuroblastoma cells.Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.

P2860

Q27002399-DB264B31-F0D5-4A0E-BF81-B6EE8132CF24 Q29619617-922ED67A-6C24-48A2-BD78-6C63D7D3BC5A Q33603605-FD933753-A474-4D07-949C-3F73401CA7A2 Q33729396-6BEC534D-DEFA-4C8E-AA56-E06B786BAAD4 Q33851843-A5376C6C-5947-40D7-9EAC-721DEA79102E Q33953822-24595EA6-B9B0-490E-97B0-4F0AEBC8952E Q35142790-E7BE86CC-5B31-4D51-9D4B-1A1051E03025 Q35799917-598855B6-2905-4CFF-8B55-17C661EA8698 Q36076772-4C1A1EEA-6FEE-4D4E-88F7-21EE11572D36 Q36102008-C26AFA42-422B-4566-83E3-9F26379EAC1F Q36280791-D184DB28-499C-4C9A-B53E-BFD3E635B431 Q36553266-F4875DD2-5D38-42C1-9BF2-252A27568BCA Q36743450-FEAAE498-61C8-4910-91D2-39B4B21C1471 Q36853236-47CD3776-C9D2-49FD-8B85-E28218239479 Q36862902-A45B05EC-66A8-4D65-971D-0DE87F518018 Q36934727-F95212C2-4A3B-46CE-A2B5-177539420156 Q37122690-1D0ED542-9784-4E13-AF8D-828EF1F4BF7F Q37205681-5F80738A-F7DD-4D88-9820-3007AE971C61 Q37362118-B8EB08B0-1CA9-4304-9D62-50B86100328A Q37372941-6481FCC3-1BB7-4952-860E-E24C616A6E0E Q37373632-8D2564CA-7C92-4EB6-87FE-E91869E128BF Q37774151-84C92DB2-024E-49DF-90FA-95FA57B5A17C Q37834139-465C4617-BC54-4F47-8D21-E1C1D40B4255 Q37968253-442C13F6-DA97-449F-ACB1-91387A44032E Q38137764-F3CEEC31-DC14-42F6-A644-D8CE763C32A4 Q38212771-7390B6C0-E222-4BAD-86B3-740C1353607F Q38233068-ED5D47A2-B9B2-4A85-BD5A-D8CB75A56080 Q38677373-AA5F3AB9-F2A9-485C-B712-ADA2FD287E8B Q38844568-9D7BEBB0-D800-4CFF-AFA3-6F8EF5B75EB5 Q38891614-04170100-296C-4CF0-9254-5176718C73BC Q41871248-3AB29394-E2A8-4EF0-946F-659BD24B80FC Q47278103-FA5545C4-0826-420E-AEC2-599AA784F4A8 Q47618719-1F803710-D270-46C5-B15E-4ACCECCFAD9B Q47710977-CFFCFFDE-5282-4741-8393-A3E2B204D173

P2860

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

http://www.wikidata.org/entity/Q33403458

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.

@ast

Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.

@en

type

label

Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.

@ast

Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.

@en

prefLabel

Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.

@ast

Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.

@en

P1433

Q33403458-6ECDD548-856D-44A3-BCAB-0021A6F15312

P1476

Q33403458-414C0038-F34C-4D5E-BFA6-7C8AB1DE7626

P2093

Q33403458-38DB2B76-CCD1-4810-B064-FB3458913209

Q33403458-5A0A3955-7E8F-4E72-8687-2ABA7288C7D6

Q33403458-7F130368-153F-4E39-9F3D-81882617397F

Q33403458-A61AAF2A-54C3-41B9-AA97-8B821AA85624

Q33403458-B7728B5D-6073-417B-B6BF-57671472686A

Q33403458-BC23BF5A-B666-469B-9614-14BE1A103CAE

Q33403458-C9E51FE1-03CB-49A8-9553-58CAEC3785EF

Q33403458-DE28D379-0BBB-4BB4-BF54-EF9EC1C88353

Q33403458-E6392258-2D19-4A84-86F0-E465C612FDE5

Q33403458-EB07255F-8193-4634-A92B-44B8F0199969

P304

Q33403458-CF438EE4-3A2B-4E44-9CA8-A914B7E7CAD1

P31

Q33403458-B1E874EB-3133-4460-B9DC-627807A9C2EB

P356

Q33403458-E0DF0419-A3D6-4ED1-84EA-05FFF69DE981

P407

Q33403458-55080589-94C8-4243-B824-F521EE4CE5D6

P433

Q33403458-BA3A85CD-53E5-4861-8411-ADA9D42029B7

P478

Q33403458-43D7EBC2-4E14-4E3D-A308-85177DFB1ABD

P50

Q33403458-B5C9C79D-6D81-46DA-AEB9-6789F12F6153

Q33403458-DF4CD7DB-A276-475F-8F3F-7A008B321544

P577

Q33403458-35D1F2DA-D7BA-48F4-B068-3C82E05CCCDE

P698

Q33403458-18B8DEE4-947F-4456-9D52-C6B546FD071B

P356

1078-0432.CCR-08-1095

P1433

Clinical Cancer Research

P1476

Inhibition of poly(ADP-ribose) ...... gainst childhood neuroblastoma

@en

P2093

Agata L Rozanska

http://www.w3.org/2001/XMLSchema#string

Deborah A Tweddle

http://www.w3.org/2001/XMLSchema#string

Deborah J Castelbuono

http://www.w3.org/2001/XMLSchema#string

E Ruth Plummer

http://www.w3.org/2001/XMLSchema#string

Evan A Mulligan

http://www.w3.org/2001/XMLSchema#string

Huw D Thomas

http://www.w3.org/2001/XMLSchema#string

Rachel A Daniel

http://www.w3.org/2001/XMLSchema#string

Steven C Clifford

http://www.w3.org/2001/XMLSchema#string

Yvette Drew

http://www.w3.org/2001/XMLSchema#string

Zdenek Hostomsky

http://www.w3.org/2001/XMLSchema#string

P304

1241-1249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1095

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19174487

http://www.w3.org/2001/XMLSchema#string